Collaboration and licensing agreement provide access to TeselaGen, the leading artificial-intelligence-enabled operating system for biotechnology
Collaboration deploys the TeselaGen AI-enabled operating system to close the gap between promising research and large-scale fermentation-based production of renewable bioproducts
LanzaTech and TeselaGen ink new 5-year deal to reduce the human carbon footprint using synthetic biology, extending their relationship through 2025
A collaboration between the Technical University of Denmark, Lawrence Berkeley National Laboratory, and TeselaGen Biotechnology, Inc. has shown that mechanistic and machine learning models can complement each other and can be combined to enable accurate genotype-to-phenotype predictions, and increase the productivity of important bioproducts produced by industrial organisms.
Ansa Biotechnologies Inc., the company developing a new way to make DNA using enzymes, is announcing a partnership with TeselaGen Biotechnology Inc., the company developing an integrated enterprise software operating system for designing, building, and optimizing biological and biochemical products.
TeselaGen Biotechnology Inc., Arzeda, the Protein Design Company™, Twist Bioscience Corporation (Nasdaq: TWST) and Labcyte Inc. have partnered to showcase a state-of-the-art DNA assembly platform (…)
Arzeda, the Protein Design CompanyTM, Twist Bioscience Corporation, TeselaGen Biotechnology Inc. and Labcyte Inc. have partnered to build a state-of-the-art DNA assembly platform to significantly reduce the time and cost required to build genes encoding Arzeda’s designed proteins. (…)
“The platform we are building with Arzeda significantly accelerates workflows by optimizing information flow. It has been an exciting collaboration that continues to expand as we move downstream into the TEST and EVOLVE modules for analytic data acquisition and analysis,” said Michael Fero, Ph.D., CEO of TeselaGen.
LanzaTech will license TeselaGen’s proprietary cloud-based informatics solution and will collaborate closely with TeselaGen, extending its state-of-the-art biological design platform to include artificial intelligence capabilities that speed up the design process.
Arzeda and TeselaGen announced that Arzeda will license TeselaGen’s proprietary cloud-based informatics solution and collaborate to extend TeselaGen’s state-of-the-art biological design automation platform.
Innovative use of molecular design technology is essential for discovering and developing new agricultural products at a faster pace. Today, TeselaGen Biotechnology Inc., and Dow AgroSciences, LLC (NYSE: DOW), announced they have entered a new phase in their collaboration to produce a state-of-the-art biological design automation platform that can speed discovery work.